Aadi Bioscience, Inc.

    Jurisdiction
    United States
    LEI
    549300G3U7TKW1M58L09
    ISIN
    US00032Q1040 (AADI)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    trending_flat 50 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    4 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    2 / 7

    Profile

    Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €18.53M
    Gross margin
    89.1%
    EBIT
    -€87.80M
    EBIT margin
    -473.8%
    Net income
    -€8.94M
    Net margin
    -48.2%

    Statement period: - (published )

    Dividends

    No dividend payouts

    Earnings Calls

    Latest earnings call: May 8, 2024

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 462K $822.58K +6.1K Buy

    Add to watchlist

    Notifications